You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

bortezomib

Showing 26 - 50 of 559
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Based on Multi-omics

Enrolling by invitation
  • Multiple Myeloma
  • Bortezomib
  • Bortezomib
  • Beijing, China
    Beijng Chao Yang Hospital
Apr 21, 2022

Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)

Withdrawn
  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • nonmyeloablative allogeneic hematopoietic stem cell transplantation
  • +7 more
  • (no location specified)
Jan 4, 2023

GVHD Trial in New York (Bortezomib, Cyclophosphamide)

Active, not recruiting
  • GVHD
  • New York, New York
    New York University School of Medicine
Apr 15, 2022

Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)

Active, not recruiting
Has Results
  • Primary Systemic Amyloidosis
  • Light Chain Deposition Disease
  • bortezomib
  • +6 more
  • Denver, Colorado
  • +6 more
Aug 24, 2022

Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, Bortezomib)

Recruiting
  • Graft-versus-host Disease
  • New York, New York
    NYU Langone Health
Mar 24, 2022

Multiple Myeloma Trial in Germany, Greece (Daratumumab, Bortezomib, Dexamethasone)

Completed
  • Multiple Myeloma
  • Berlin, Germany
  • +9 more
May 27, 2022

Hematological Malignancy Trial in Detroit (Bortezomib)

Recruiting
  • Hematological Malignancy
  • Bortezomib
  • Detroit, Michigan
    Henry Ford hospital
Dec 23, 2021

Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))

Active, not recruiting
Has Results
  • Lymphoma, Mantle Cell
  • Mantle Cell Lymphoma
  • Rituximab (R)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021

Multiple Myeloma Trial in Chicago, Milwaukee (Bortezomib, Isatuximab, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Bortezomib
  • +3 more
  • Chicago, Illinois
  • +1 more
Mar 14, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Bortezomib
  • +4 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Aug 5, 2022

Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)

Active, not recruiting
  • Lymphoma
  • Relapsed/Refractory T-cell Lymphomas
  • Stanford, California
  • +10 more
Feb 2, 2023

Plasma Cell Myeloma Trial in Worldwide (lenalidomide, bortezomib, cyclophosphamide)

Active, not recruiting
  • Plasma Cell Myeloma
  • Nantes Cedex 01, France
  • +11 more
May 3, 2022

Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease Trial in Mexico City (Bortezomib)

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • Bortezomib
  • Mexico City, Mexico
    Hospital General de México "Dr. Eduardo Liceaga"
Jan 2, 2022

Multiple Myeloma Trial in Guangzhou (Selinexor, Bortezomib, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Guangzhou, Guangdong, China
  • +3 more
Aug 16, 2022

Multiple Myeloma Trial in Washington, Hackensack (Melphalan, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Washington, District of Columbia
  • +1 more
May 6, 2022

Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin Trial in Ann Arbor (Bortezomib, Ruxolitinib)

Completed
  • Hodgkin's Lymphoma
  • Lymphoma, Non-Hodgkin
  • Ann Arbor, Michigan
    University of Michgan Comprehensive Cancer Center
Dec 3, 2021

Hypophosphatasia Trial (methotrexate, rituximab, bortezomib)

Not yet recruiting
  • Hypophosphatasia
  • (no location specified)
Aug 23, 2023

Multiple Myeloma Trial in Germany (Teclistamab (Tec), Daratumumab, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Teclistamab (Tec)
  • +4 more
  • Berlin, Germany
  • +8 more
Jan 19, 2023

Maintenance With Bortezomib Plus Daratumumab After Induction

Recruiting
  • Multiple Myeloma
  • Non-eligible for Autologous Stem Cell Transplantation (ASCT)
  • Arganda Del Rey, Spain
  • +31 more
Sep 15, 2022

Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)

Not yet recruiting
  • Newly Diagnosed Multiple Myeloma
  • Hamburg, Germany
  • +3 more
Dec 16, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)

Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Bortezomib
  • +3 more
  • Los Angeles, California
  • +1 more
Aug 19, 2022

Multiple Myeloma Trial in Atlanta (Bortezomib, Lenalidomide, Dexamethasone)

Completed
  • Multiple Myeloma
  • Bortezomib
  • +3 more
  • Atlanta, Georgia
    Emory University Winship Cancer Institute
Nov 1, 2021

Multiple Myeloma Trial in United States (Bortezomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Bortezomib
  • +2 more
  • Denver, Colorado
  • +7 more
Feb 11, 2022

Multiple Myeloma Trial in United States (Lenalidomide, Elotuzumab, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Atlanta, Georgia
  • +6 more
Dec 17, 2021

Multiple Myeloma Trial in Denmark, Ireland (Isatuximab, Bortezomib, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Aarhus, Denmark
  • +5 more
Jul 29, 2022